Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology Group (GOIM)

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 943-948

  Gebbia, Vittorio ^a   Borsellino, Nicolò ^a   Testa, Antonio ^a   Latteri, Mario Adelfio ^a   Milia, Valerio ^b   Valdesi, Matteo ^c   Giotta, Francesco ^d   Gebbia, Nicolò ^a   Colucci, Giuseppe ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b Service of Medical Oncology   (Italy)

^c Buccheri La Ferla Hospital   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Breast cancer; Cisplatin; Epirubicin; Lonidamine

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LONIDAMINE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG CYTOTOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0031472882     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00005     Document Type: Article

References (35)

1. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
2. Colucci G, Romito S, Gebbia V, et al. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM). Br J Cancer 1995; 72: 1245-50.
3. Colucci G, Giotta F, Gebbia V, et al. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group. Anti-Cancer Drugs 1997; 8: 257-64.
4. Stewart DJ, Evans WK, Sheperd FA, et al. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 1997; 15: 1897-905.
5. Smith G, Henderson IC. New treatments for breast cancer. Semin Oncol 1996; 23: 506-28.
6. Razak E, Valeriote F, Vietti T. Survival of hematopoietic and leukemia colony forming cells in vitro following administration of adunorubicin or adriamycin. Cancer Res 1972; 32: 1496-500.
7. Frei E, Cannellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-94.
8. Yates JW, Glidewell O, Wiernik P, Jones S, Dutcher J. Activity of daunorubicin versus adriamycin induction and monthly versus bimonthly maintenance in acute myelocytic leukemia. Blood 1982; 60: 454-62.
9. Cortes EP, Holland JF, Glidewell O. Amputation and adriamycin in primary osteosarcoma: a five year report. Cancer Treat Rep 1978; 62: 271-7.
10. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14: 65-74.
11. Tannock IF, Boyed NF, de Boer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
12. French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9: 305-12.
13. Habeshaw T, Paul J, Jones R, et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991; 9: 34-6.
14. Marschner N, Kreienberg R, Souchon R, et al. Evaluation of the importance and relevance of dose intensity using epirubicin and cylcophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Semin Oncol 1994; 21: 10-16.
15. Forestiere AA, Hakes TB, Wittes JI. Cis-platinum in the treatment of metastatic breast carcinoma. Am J Clin Oncol 1982; 5: 243-7.
16. Ferrero B, Gebbia V, Cannata G, et al. Cisplatin and VP16 as salvage treatment for advanced breast carcinoma resistant or recurrent after first line chemotherapy for metastatic disease. Oncol Rep 1995; 2: 122-5.
17. Hortobagyi GN: Is cisplatin useful for breast cancer? Eur J Cancer Clin Oncol 1987; 23: 119-21.
18. Slegde GW, Roth BJ. Cisplatin in the management of breast cancer. Semin Oncol 1989; 16: 110-5.
19. Slegde GW. Cisplatin and platinum analogues in breast cancer. Semin Oncol 1992; 19: 78-82.
20. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. Lonidamine, a selective inhibitor of aerobic gly colysis of murine tumor cells. J Natl Cancer Inst 1981; 66: 497-9.
21. Silvestrini R. Lonidamine: an overview. Semin Oncol 1991; 18: 2-6.
22. Kim JH, Alfieri AA, Kim SH, et al. Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 1986; 46: 1120-3.
23. Teicher BA, Holden SA, Herman TS, Frei E, III. Modulation of alkylating agents by lonidamine in vivo. Semin Oncol 1991; 18 (suppl 4): 7-10.
24. De Bufolo D, Zupi G. In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. Int J Oncol 1994; 4: 737-40.
25. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992; 52: 813-7.
26. Raaphorts GP, Ko D, Feeley MM, Dajoux CE, Maroun J, Evans WK. The effect of lonidamine alone and in combination with cisplatin on the in vitro growth and viability of lung squamous cell carcinoma cell lines. Anticancer Res 1991; 11: 41-8.
27. Band PR, Maroun J, Pritchard K et al. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trial Group Study. Cancer Treat Rep 1986; 70: 1305-10.
28. Possinger K, Wagner H, Kovacs S, Flath B, Classen S, Wilmanns. Lonidamine in high-risk breast cancer patients. Semin Oncol 1991; 18 (suppl 4): 58-61.
29. De Lena M, De Mitrio A, Catino AM, Lorusso V, Brandi M. Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer preliminary results. Int J Oncol 1994; 4: 779-82.
30. Tomirotti M, Bernardo G, Epifani C, et al. Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 1993; 3: 213-7.
31. Calabresi F, Marolla P, Di Lauro L, et al. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide versus fluourouracil. doxombicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. Semin Oncol 1991; 18 (suppl 4): 66-72.
32. Dogliotti L, Berruti A, Buniva T, et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 19??; 14: 1165-72.
33. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
34. Basser RL, Sabal MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancies. J Clin Oncol 1994; 12: 1659-66.
35. Iaffaioli RV, Tortoriello A, Facchini G, et al. Alpha-2b-IFN, HDEDX, CDDP and lonidamine in advanced breast cancer (ABC). Preliminary data of a randomized phase II study. Proc Am Soc Clin Oncol 1997; 16: 173.